You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Medtronic
Colorcon
McKinsey
Express Scripts

Last Updated: November 25, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BUPRENORPHINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Buprenorphine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00637000 Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone Completed Indivior Inc. Phase 2 2008-03-01 The purpose of this study is to compare the presence, degree, time course and profile of opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine or buprenorphine/naloxone in persons with active opioid dependence. The primary outcome measure is the severity of withdrawal symptoms measured using the Clinical Opiate Withdrawal Scale (COWS). The primary study hypothesis is that neither drug formulation will precipitate an opioid withdrawal syndrome.
New Dosage NCT03608696 Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure Not yet recruiting Chiesi Farmaceutici S.p.A. Phase 1/Phase 2 2018-08-29 Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine. These results were with an empirically derived dose. This study will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship and use a rational approach to define an optimal dose regimen. The clinical trial will be open label, single arm design with a goal of initial testing of a new dosing regimen.
New Dosage NCT03608696 Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure Not yet recruiting Thomas Jefferson University Phase 1/Phase 2 2018-08-29 Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine. These results were with an empirically derived dose. This study will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship and use a rational approach to define an optimal dose regimen. The clinical trial will be open label, single arm design with a goal of initial testing of a new dosing regimen.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Buprenorphine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000200 Cocaine Effects in Humans: Physiology and Behavior - 1 Completed Columbia University Phase 2 1997-01-01 The purpose of this study is to compare the effects of buprenorphine or methadone maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving, in opiate-dependent cocaine users.
NCT00000200 Cocaine Effects in Humans: Physiology and Behavior - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 1997-01-01 The purpose of this study is to compare the effects of buprenorphine or methadone maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving, in opiate-dependent cocaine users.
NCT00000202 Buprenorphine Maintenance for Opioid Addicts - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 1988-08-01 The purpose of this study is to evaluate the efficacy of buprenorphine and desipramine in treatment of opiate and cocaine dependence.
NCT00000202 Buprenorphine Maintenance for Opioid Addicts - 1 Completed Yale University Phase 2 1988-08-01 The purpose of this study is to evaluate the efficacy of buprenorphine and desipramine in treatment of opiate and cocaine dependence.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Buprenorphine

Condition Name

Condition Name for Buprenorphine
Intervention Trials
Opioid-Related Disorders 93
Opioid-use Disorder 36
Opioid Dependence 35
Heroin Dependence 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Buprenorphine
Intervention Trials
Opioid-Related Disorders 148
Substance-Related Disorders 58
Disease 43
Heroin Dependence 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Buprenorphine

Trials by Country

Trials by Country for Buprenorphine
Location Trials
Japan 29
United Kingdom 26
Germany 10
Norway 8
Denmark 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Buprenorphine
Location Trials
New York 75
California 71
Florida 63
Pennsylvania 59
Maryland 54
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Buprenorphine

Clinical Trial Phase

Clinical Trial Phase for Buprenorphine
Clinical Trial Phase Trials
Phase 4 74
Phase 3 98
Phase 2/Phase 3 12
[disabled in preview] 105
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Buprenorphine
Clinical Trial Phase Trials
Completed 236
Not yet recruiting 70
Recruiting 50
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Buprenorphine

Sponsor Name

Sponsor Name for Buprenorphine
Sponsor Trials
National Institute on Drug Abuse (NIDA) 139
Yale University 30
Purdue Pharma LP 27
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Buprenorphine
Sponsor Trials
Other 389
Industry 169
NIH 148
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
McKinsey
Johnson and Johnson
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.